



#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Samuel F. Hunter, M.D.

For:

Method for Treatment of Demyelinating Central Nervous System

Disease

)

Filing Date:

October 16, 2003

Group Art Unit:

1646

Examiner:

Not yet assigned

Attorney's Docket No.

11918N/021452

Customer No.:

32885

Secial No :

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
(SUBMISSION BEFORE MAILING DATE OF A FIRST ACTION ON THE MERITS)

Mail Stop IDS Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 June 15, 2004

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and §1.98, applicants hereby submit an Information Disclosure Statement for consideration by the Examiner.

#### I. List of Patents, Publications or Other Information

The Patents, publications, or other information submitted for consideration by the Office are listed below and on the PTO-1449(s), attached hereto.

# II. Copies

The Patents and other publications listed on the attached Form PTO-1449 are in the English language or an English language abstract is provided.

The application was filed on October 16, 2003. In view of the waiver of the requirement under 37 C.F.R. § 1.98(a)(2)(i) published in the Official Gazette on August 5, 2003, for applications filed after June 30, 2003, copies of the cited U.S. Patents are not attached. A copy of WO 00/77028 A1 and WO 02/13862 A2 is provided.

## III. Concise Explanation of Relevance

The attached documents, publications, and/or other information attached hereto are in the English language or a translation is provided. Thus, a statement of relevancy is not required.

#### IV. Fees

The IDS is being filed under 37 C.F.R. §1.97(b); before mailing date of a first action on the merits, whichever event occurs last. No fee or statement is required.

### V. Payment of Fees

No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned.

Respectfully submitted,

Richard S. Myers, Jr.

Registration No. 42,022

STITES & HARBISON PLLC

424 Church Street, Suite 1800

SunTrust Center

Nashville, TN 37219-2376

(615) 244-5200

Customer No. 32885

Attorney for Applicant



### CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this Supplemental Information Disclosure Statement, Form PTO-1449, Prior Art References, and Return Receipt Postcard are being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop IDS Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on June 15, 2004.

Richard S. Myers, Jr.

Registration No. 42,022

Date

11918N:021452:583953:1:NASHVILLE

Comparable to					cket No.	Serial	Serial No.		
Form PTO-1449	Patent & Trademark Office			11918N/021452		10/69	10/007 570		
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Customer No. 32885			10/687,576		
				Guotomi	J. 110. 02000				
					nt	<u>_</u>			
JUH 7 8 2004 E				Samuel	F. Hunter		•		
				Filing Da	 nte	Group			
TIME TRANSPORT					ber 16, 200				
Examiner		_		I				ng Date	
Initial	Document No.	Date	Name		Class	Subclass	ubclass If Appropriate		
				<del></del>					
ļ									
		FOREIGN PA	TENT DOCUMEN	NTS			<u> </u>		
	, onlean, men personal					T	Translation		
	Document No.	Date	Name		Class	Subclass	Yes No		
)	PCT/US03/32716	October 16, 2003	Hunter						
	WO 00/77028 A1	December 21, 2000	<u> </u>			ļ			
U	WO 02/13862 A2	February 21, 2002	· ·						
:	DARTIO OM		EOUS DOCUMEN		na Dam Julai - 4	Call Laural D	1	ha Maslatini I	
		et al.; <u>Interferon-β inl</u> urologica Belgica; Be				Leii Levei Ke	nevance 1	io iviuitipie	
;						Cells; Cytok	ine; Vol.	13; No. 5;	
:		HUANG, et al.; <u>Interferon-Beta Induces the Development of Type 2 Dendritic Cells</u> ; Cytokine; Vol. 13; No. 5; March 2001; pp. 264-271.							
	HAYASHI, et al.; <u>Granulocyte – Macrophage Colony Stimulating Factor Inhibits Class II Major</u> Histocompatibility Complex Expression and Antigen Presentation by Microglia; Journal of Neuroimmunology;								
			anu Anugen Pi	i esciliatioi	oy microgii	<u>a,</u> journal of	Menioliu	munology;	
	DUDDY, et al.; M	Vol. 48; No. 1; 1993; pp. 23-32.  DUDDY, et al.; Monocyte-Derived Dendritic Cells: A Potential Target for Therapy in Mulitple Sclerosis (MS);							
		imental Immunology;					<u> </u>		
		I.; Multiple Sclerosis Vol. 54; No. 11; 13 J				Granulocyte	Colony-S	Stimulating	
Examiner:	Tractor, Neurology,	v oi. 54, No. 11, 15 J		onsidered	•				
*Examiner: Initial if c	itation considered, whe	ther or not citation is in	conformance wi	th MPFP 6	09: draw line t	through citatio	n if not in		
1	nce and not considered					•			

Page 2 of 2

Comparable to Form PTO-1449	U.S. Department of Commerce Patent & Trademark Office			Atty. Docket No. 11918N/021452			Serial No. 10/687,576				
		ATION DISCLOSURE CITATION several sheets if necessary)			Customer No. 32885						
				Applicant							
					Samuel F. Hunter						
					ate ober 16, 200		Group 1646				
Examiner Initial	Document No. Date		Nan	ne	ne Class		Filing Date If Appropriate				
	<del>                                     </del>	<del></del>			<u> </u>						
	+		<del></del>		<del> </del>		<del>                                     </del>				
	+		+		+						
			+	<del></del>	<del>                                     </del>						
					1						
			<b>_</b>								
			<del> </del>								
	<del>                                     </del>						<del> </del>				
			+			-		<del></del>			
	+										
	<u> </u>	FOREIGN	PATENT DOCUME	NTS	ابــــــــــــــــــــــــــــــــــــ	<u></u>	-				
			-			Tran	nslation				
	Document No.	Date Nar		ne Class		Subclass	Yes	No			
	.										
					1						
			ANEOUS DOCUME								
	MCQUALTER, et										
	Target in Multiple Spp. 873-881.	Scierosis; Journal	of Experimental	Miedicine,	Tokyo, JP; v	01. 194; No.	7; 1 Oct	ober 2001;			
		crophage and Mic	roglial Response	to Cytoki	ines In Vitro:	Phagocytic /	Activity	Proteolytic			
<i>y</i>	SMITH, et al.; Macrophage and Microglial Responses to Cytokines In Vitro: Phagocytic Activity, Proteolytic Enzyme Release, and Free Radical Production; Journal of Neuroscience Research; Vol. 54; No. 1; 1 October										
	1998; pp. 68-78.										
	ZAVALA, et al.; G-CSF Therapy of Ongoing Experimental Allergic Encephalomyelitis Via Chemokine- and Cytokin-Based Immune Deviation; The Journal of Immunology; Vol. 168; No. 4; 15 February 2002; pp. 2011-										
	2019.										
Examiner:			Date (	Considered							
			-								